title: Pharmacokinetics of enrofloxacin following oral and subcutaneous administration in the common ringtail possum (Pseudocheirus peregrinus).
abstract: [Correction added on 23 March 2015, after first online publication: Terminal half-life values of enrofloxacin is corrected in the fourth sentence of the abstract] Clinically healthy common ringtail possums (n = 5) received single doses of 10 mg/kg enrofloxacin orally and then 2 weeks later subcutaneously. Serial plasma samples were collected over 24 h for each treatment phase, and enrofloxacin concentrations were determined using a validated HPLC assay. Pharmacokinetic parameters were determined by noncompartmental analysis. Following oral administration, plasma concentrations were of therapeutic relevance (Cmax median 5.45 μg/mL, range 2.98-6.9 μg/mL), with terminal-phase half-life (t½ ) shorter than in other species (median 3.09 h, range 1.79-5.30 h). In contrast, subcutaneous administration of enrofloxacin did not achieve effective plasma concentrations, with plasma concentrations too erratic to fit the noncompartmental model except in one animal. On the basis of the AUC:MIC, enrofloxacin administered at 10 mg/kg orally, but not subcutaneously, is likely to be effective against a range of bacterial species that have been reported in common ringtail possums.
authors.affiliation: Australian Wildlife Health Centre, Healesville Sanctuary, Healesville, Vic., Australia.
authors.forename: T F
authors.initials: TF
authors.lastname: Scheelings
authors.affiliation: Translational Research and Animal Clinical Trial Study (TRACTS) Group, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Melbourne, Vic., Australia.
authors.forename: J L
authors.initials: JL
authors.lastname: Devi
authors.affiliation: Translational Research and Animal Clinical Trial Study (TRACTS) Group, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Melbourne, Vic., Australia.
authors.forename: A P
authors.initials: AP
authors.lastname: Woodward
authors.affiliation: Translational Research and Animal Clinical Trial Study (TRACTS) Group, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Melbourne, Vic., Australia.
authors.forename: T
authors.initials: T
authors.lastname: Whittem
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid / Q000662:veterinary; D002939:Ciprofloxacin / Q000097:blood; D000077422:Enrofloxacin; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D007279:Injections, Subcutaneous / Q000662:veterinary; D008297:Male; D048329:Phalangeridae / Q000097:blood / Q000378:metabolism*
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D000077422:Enrofloxacin; D002939:Ciprofloxacin